PDS Biotech licenses TARP from National Cancer Institute

By The Science Advisory Board staff writers

November 8, 2021 -- PDS Biotechnology has licensed the tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP) from the U.S. National Cancer Institute (NCI).

The worldwide nonexclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034. TARP is used to treat myeloid leukemia and prostate and breast cancers.

PDS Biotech said it is exploring the effectiveness of its candidate PDS0102, which is made using PDS Biotechnology's Versamune T-cell-activating platform and TARP.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.